Norden Group LLC Buys Shares of 24,673 Castle Biosciences, Inc. (NASDAQ:CSTL)

Norden Group LLC purchased a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTLFree Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 24,673 shares of the company’s stock, valued at approximately $547,000. Norden Group LLC owned 0.09% of Castle Biosciences at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Olympiad Research LP acquired a new stake in Castle Biosciences during the 4th quarter worth approximately $263,000. Principal Financial Group Inc. raised its holdings in shares of Castle Biosciences by 7.0% during the fourth quarter. Principal Financial Group Inc. now owns 1,585,673 shares of the company’s stock worth $34,219,000 after acquiring an additional 103,503 shares during the period. Bellevue Group AG lifted its position in Castle Biosciences by 0.4% in the 4th quarter. Bellevue Group AG now owns 1,232,378 shares of the company’s stock valued at $26,595,000 after acquiring an additional 4,347 shares in the last quarter. Walleye Capital LLC acquired a new position in Castle Biosciences in the 3rd quarter worth $2,885,000. Finally, Banque Pictet & Cie SA increased its holdings in Castle Biosciences by 10.6% during the 3rd quarter. Banque Pictet & Cie SA now owns 203,275 shares of the company’s stock worth $3,433,000 after purchasing an additional 19,472 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Castle Biosciences Stock Performance

Shares of CSTL stock opened at $17.48 on Thursday. Castle Biosciences, Inc. has a 12 month low of $12.07 and a 12 month high of $25.91. The company’s fifty day simple moving average is $22.70 and its 200-day simple moving average is $21.90. The firm has a market cap of $482.57 million, a PE ratio of -15.20 and a beta of 0.93. The company has a quick ratio of 9.02, a current ratio of 9.25 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTLGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.28. The firm had revenue of $72.97 million for the quarter, compared to analysts’ expectations of $68.34 million. Castle Biosciences had a negative net margin of 12.28% and a negative return on equity of 7.91%. Equities research analysts expect that Castle Biosciences, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird restated an “outperform” rating and issued a $34.00 price target on shares of Castle Biosciences in a report on Friday, July 5th.

Read Our Latest Stock Report on CSTL

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,368 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $23.40, for a total transaction of $55,411.20. Following the transaction, the insider now owns 57,893 shares of the company’s stock, valued at approximately $1,354,696.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Derek J. Maetzold sold 1,947 shares of Castle Biosciences stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $20.35, for a total transaction of $39,621.45. Following the completion of the transaction, the insider now owns 65,418 shares in the company, valued at $1,331,256.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Derek J. Maetzold sold 2,368 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $23.40, for a total value of $55,411.20. Following the completion of the sale, the insider now owns 57,893 shares in the company, valued at approximately $1,354,696.20. The disclosure for this sale can be found here. Insiders sold a total of 30,427 shares of company stock worth $736,715 over the last ninety days. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Company Profile

(Free Report)

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.

Further Reading

Institutional Ownership by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.